Benign Prostatic Hyperplasia Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1066204
  • May 2021
  • Pharmaceuticals
  • 129 Pages
The Benign Prostatic Hyperplasia Therapeutics market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Benign Prostatic Hyperplasia Therapeutics market research report recommends a business strategy for present market participants to strengthen their position in the market.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Astellas Pharma., Allergan plc., Abbott Laboratories, Boehringer Ingelheim Pharma GmbH and Co, Merck & Co., Inc., GlaxoSmithKline plc, Nymox Pharmaceutical, Ipsen S. A, Eli Lilly and Company, Sanofi
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Impact Analysis
The analysis of covid-19 is based on the impact of the current pandemic situation on market scenarios. This includes impact of covid-19 outbreak on overall revenue, market segments as well as regional market. The report also puts light on detailed impact analysis by taking into consideration all the government policies imposed during the pandemic situation, temporary shutdown of manufacturing units, current state of supply chain and distributors, and its future impacts on the growth of overall market. The market study will assist user to understand the global demand and impose strategic business plans to compete with the peers.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Benign Prostatic Hyperplasia Therapeutics market along with their effects over the forecast period. Similarly, according to the region Benign Prostatic Hyperplasia Therapeutics market research report includes the study of opportunities available in the market situation.

The Benign Prostatic Hyperplasia Therapeutics market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.

Major Key Players for Global Benign Prostatic Hyperplasia Therapeutics Market:
The Benign Prostatic Hyperplasia Therapeutics market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Astellas Pharma., Allergan plc., Abbott Laboratories, Boehringer Ingelheim Pharma GmbH and Co, Merck & Co., Inc., GlaxoSmithKline plc, Nymox Pharmaceutical, Ipsen S. A, Eli Lilly and Company, Sanofi

Benign Prostatic Hyperplasia Therapeutics Market Segmentation Analysis:
by Product
Alpha blocker
5-Alpha reductase inhibitor
Phosphodiesterase-5 inhibitor
Others
By Therapy
Mono drug therapy
Combination drug therapy

Global Benign Prostatic Hyperplasia Therapeutics Market Segmentation by Regions:
In regional analysis, Benign Prostatic Hyperplasia Therapeutics market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Benign Prostatic Hyperplasia Therapeutics market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Benign Prostatic Hyperplasia Therapeutics Market: Value and Forecast
  • U.S.
  • Canada
 Europe Region for Benign Prostatic Hyperplasia Therapeutics Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 Asia Pacific Region for Benign Prostatic Hyperplasia Therapeutics Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 Latin America Region for Benign Prostatic Hyperplasia Therapeutics Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 Middle East and Africa for Benign Prostatic Hyperplasia Therapeutics Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa


Important Points Covered by Report:
  • To analyze the value of the Benign Prostatic Hyperplasia Therapeutics market, according to the key region.
  • To study the Benign Prostatic Hyperplasia Therapeutics market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Benign Prostatic Hyperplasia Therapeutics market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Benign Prostatic Hyperplasia Therapeutics research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Benign Prostatic Hyperplasia Therapeutics market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Benign Prostatic Hyperplasia Therapeutics market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Benign Prostatic Hyperplasia Therapeutics market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Benign Prostatic Hyperplasia Therapeutics market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Benign Prostatic Hyperplasia Therapeutics market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Astellas Pharma.
  • Allergan plc.
  • Abbott Laboratories
  • Boehringer Ingelheim Pharma GmbH and Co
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Nymox Pharmaceutical
  • Ipsen S. A
  • Eli Lilly and Company
  • Sanofi
  • Alpha blocker
  • 5-Alpha reductase inhibitor
  • Phosphodiesterase-5 inhibitor
  • Others
  • Mono drug therapy
  • Combination drug therapy

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Benign Prostatic Hyperplasia Therapeutics Market Snapshot
          2.1.1. Global Benign Prostatic Hyperplasia Therapeutics Market By Product,2019
               2.1.1.1.Alpha blocker
               2.1.1.2.5-Alpha reductase inhibitor
               2.1.1.3.Phosphodiesterase-5 inhibitor
               2.1.1.4.Others
          2.1.2. Global Benign Prostatic Hyperplasia Therapeutics Market By Therapy,2019
               2.1.2.1.Mono drug therapy
               2.1.2.2.Combination drug therapy
          2.1.3. Global Benign Prostatic Hyperplasia Therapeutics Market By End-use,2019
          2.1.4. Global Benign Prostatic Hyperplasia Therapeutics Market By Geography,2019

3. Global Benign Prostatic Hyperplasia Therapeutics Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Product, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Product, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Product, 2020
     4.2. Global Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Product, 2018 – 2028

5. Global Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Therapy, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Therapy, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Therapy, 2020
     5.2. Global Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Therapy, 2018 – 2028

6. Global Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By End-use, 2018 – 2028

7. Global Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Benign Prostatic Hyperplasia Therapeutics Market Analysis, 2018 – 2028 
          7.2.1. North America Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Product, 2018 – 2028
          7.2.3. North America Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Therapy, 2018 – 2028
          7.2.4. North America Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Benign Prostatic Hyperplasia Therapeutics Market Analysis, 2018 – 2028 
          7.3.1.  Europe Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Product, 2018 – 2028
          7.3.3. Europe Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Therapy, 2018 – 2028
          7.3.4. Europe Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Product, 2018 – 2028
          7.4.3. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Therapy, 2018 – 2028
          7.4.4. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Benign Prostatic Hyperplasia Therapeutics Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Product, 2018 – 2028
          7.5.3. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Therapy, 2018 – 2028
          7.5.4. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Benign Prostatic Hyperplasia Therapeutics Market Analysis, 2018 – 2028 
          7.6.1.  MEA Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Product, 2018 – 2028
          7.6.3. MEA Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By Therapy, 2018 – 2028
          7.6.4. MEA Benign Prostatic Hyperplasia Therapeutics Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Benign Prostatic Hyperplasia Therapeutics Providers
        8.4.1 Astellas Pharma.
                8.4.1.1 Business Description
                8.4.1.2 Astellas Pharma. Geographic Operations
                8.4.1.3 Astellas Pharma. Financial Information
                8.4.1.4 Astellas Pharma. Product Positions/Portfolio
                8.4.1.5 Astellas Pharma. Key Developments
        8.4.2 Allergan plc.
                8.4.2.1 Business Description
                8.4.2.2 Allergan plc. Geographic Operations
                8.4.2.3 Allergan plc. Financial Information
                8.4.2.4 Allergan plc. Product Positions/Portfolio
                8.4.2.5 Allergan plc. Key Developments
        8.4.3 Abbott Laboratories
                8.4.3.1 Business Description
                8.4.3.2 Abbott Laboratories Geographic Operations
                8.4.3.3 Abbott Laboratories Financial Information
                8.4.3.4 Abbott Laboratories Product Positions/Portfolio
                8.4.3.5 Abbott Laboratories Key Developments
        8.4.4 Boehringer Ingelheim Pharma GmbH and Co
                8.4.4.1 Business Description
                8.4.4.2 Boehringer Ingelheim Pharma GmbH and Co Geographic Operations
                8.4.4.3 Boehringer Ingelheim Pharma GmbH and Co Financial Information
                8.4.4.4 Boehringer Ingelheim Pharma GmbH and Co Product Positions/Portfolio
                8.4.4.5 Boehringer Ingelheim Pharma GmbH and Co Key Developments
        8.4.5 Merck & Co., Inc.
                8.4.5.1 Business Description
                8.4.5.2 Merck & Co., Inc. Geographic Operations
                8.4.5.3 Merck & Co., Inc. Financial Information
                8.4.5.4 Merck & Co., Inc. Product Positions/Portfolio
                8.4.5.5 Merck & Co., Inc. Key Developments
        8.4.6 GlaxoSmithKline plc
                8.4.6.1 Business Description
                8.4.6.2 GlaxoSmithKline plc Geographic Operations
                8.4.6.3 GlaxoSmithKline plc Financial Information
                8.4.6.4 GlaxoSmithKline plc Product Positions/Portfolio
                8.4.6.5 GlaxoSmithKline plc Key Developments
        8.4.7 Nymox Pharmaceutical
                8.4.7.1 Business Description
                8.4.7.2 Nymox Pharmaceutical Geographic Operations
                8.4.7.3 Nymox Pharmaceutical Financial Information
                8.4.7.4 Nymox Pharmaceutical Product Positions/Portfolio
                8.4.7.5 Nymox Pharmaceutical Key Developments
        8.4.8 Ipsen S. A
                8.4.8.1 Business Description
                8.4.8.2 Ipsen S. A Geographic Operations
                8.4.8.3 Ipsen S. A Financial Information
                8.4.8.4 Ipsen S. A Product Positions/Portfolio
                8.4.8.5 Ipsen S. A Key Developments
        8.4.9 Eli Lilly and Company
                8.4.9.1 Business Description
                8.4.9.2 Eli Lilly and Company Geographic Operations
                8.4.9.3 Eli Lilly and Company Financial Information
                8.4.9.4 Eli Lilly and Company Product Positions/Portfolio
                8.4.9.5 Eli Lilly and Company Key Developments
        8.4.10 Sanofi
                8.4.10.1 Business Description
                8.4.10.2 Sanofi Geographic Operations
                8.4.10.3 Sanofi Financial Information
                8.4.10.4 Sanofi Product Positions/Portfolio
                8.4.10.5 Sanofi Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Benign Prostatic Hyperplasia Therapeutics Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Benign Prostatic Hyperplasia Therapeutics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Benign Prostatic Hyperplasia Therapeutics Market Revenue, By Therapy, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Benign Prostatic Hyperplasia Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Benign Prostatic Hyperplasia Therapeutics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Benign Prostatic Hyperplasia Therapeutics Market Revenue, By Therapy, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Benign Prostatic Hyperplasia Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Revenue, By Therapy, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Benign Prostatic Hyperplasia Therapeutics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Benign Prostatic Hyperplasia Therapeutics Market Revenue, By Therapy, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Benign Prostatic Hyperplasia Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Benign Prostatic Hyperplasia Therapeutics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Benign Prostatic Hyperplasia Therapeutics Market Revenue, By Therapy, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Benign Prostatic Hyperplasia Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Benign Prostatic Hyperplasia Therapeutics: Market Segmentation 
FIG. 2 Global Benign Prostatic Hyperplasia Therapeutics Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Benign Prostatic Hyperplasia Therapeutics Market, By Product, 2019 (US$ Mn) 
FIG. 5 Global Benign Prostatic Hyperplasia Therapeutics Market, By Therapy, 2019 (US$ Mn) 
FIG. 6 Global Benign Prostatic Hyperplasia Therapeutics Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Benign Prostatic Hyperplasia Therapeutics Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Benign Prostatic Hyperplasia Therapeutics Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Benign Prostatic Hyperplasia Therapeutics Providers, 2019
FIG. 11 Global Benign Prostatic Hyperplasia Therapeutics Market Revenue Contribution, By Product, 2019 & 2028 (Value %) 
FIG. 12 Global Benign Prostatic Hyperplasia Therapeutics Market Revenue Contribution, By Therapy, 2019 & 2028 (Value %) 
FIG. 13 Global Benign Prostatic Hyperplasia Therapeutics Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Benign Prostatic Hyperplasia Therapeutics Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Benign Prostatic Hyperplasia Therapeutics market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Benign Prostatic Hyperplasia Therapeutics Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Benign Prostatic Hyperplasia Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  North America Benign Prostatic Hyperplasia Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  North America Benign Prostatic Hyperplasia Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Europe Benign Prostatic Hyperplasia Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  Europe Benign Prostatic Hyperplasia Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  Europe Benign Prostatic Hyperplasia Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Latin America Benign Prostatic Hyperplasia Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Benign Prostatic Hyperplasia Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Benign Prostatic Hyperplasia Therapeutics Market Value, By Country, 2018 – 2028
TABLE  MEA Benign Prostatic Hyperplasia Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  MEA Benign Prostatic Hyperplasia Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  MEA Benign Prostatic Hyperplasia Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Astellas Pharma.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Allergan plc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Abbott Laboratories: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Boehringer Ingelheim Pharma GmbH and Co: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Merck & Co., Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Nymox Pharmaceutical: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Ipsen S. A: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Eli Lilly and Company: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sanofi: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Benign Prostatic Hyperplasia Therapeutics Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Benign Prostatic Hyperplasia Therapeutics Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Benign Prostatic Hyperplasia Therapeutics Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Benign Prostatic Hyperplasia Therapeutics Market, By Geography, 2019 (US$ Mn)
FIG.  Global Benign Prostatic Hyperplasia Therapeutics Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Benign Prostatic Hyperplasia Therapeutics Providers, 2016
FIG.  Global Benign Prostatic Hyperplasia Therapeutics Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global 5-Alpha reductase inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Phosphodiesterase-5 inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Benign Prostatic Hyperplasia Therapeutics Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Combination drug therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Benign Prostatic Hyperplasia Therapeutics Market Value, 2018 – 2028, (US$ Mn)